PPA
RAPT

Parametric Portfolio Associates’s RAPT Therapeutics RAPT Stock Holding History

Parametric Portfolio Associates’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-949
Closed -$279K – 3750
2021
Q4 		$279K Sell
949
-3,428
-78% -$916K ﹤0.01% 3307
2021
Q3 		$1.09M Buy
4,377
+931
+27% +$246K ﹤0.01% 2770
2021
Q2 		$876K Buy
+3,446
New +$644K ﹤0.01% 2828

Other funds holding RAPT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Parametric Portfolio Associates's RAPT Position: Q1 2022 in Review

Parametric Portfolio Associates sold out of RAPT Therapeutics (RAPT) in Q1 2022, closing a stake of 949 shares — an estimated $279K sold.

Parametric Portfolio Associates first reported a position in RAPT in Q2 2021 and held it in 3 quarters. The position peaked at $1.09M in Q3 2021. 85 funds tracked by Wall St. Rank hold RAPT as of Q1 2022.

  • Parametric Portfolio Associates reported no remaining RAPT Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Parametric Portfolio Associates sold 949 RAPT Therapeutics shares in Q1 2022, an estimated $279K.
  • Parametric Portfolio Associates first reported a position in RAPT Therapeutics in Q2 2021 and held it in 3 quarters.
  • Parametric Portfolio Associates's RAPT Therapeutics position peaked at $1.09M in Q3 2021.
  • 85 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.